AZN vs LLY
AstraZeneca PLC and ELI Lilly & Co., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AZN | LLY |
|---|---|---|
| Revenue | $58.7B | $65.2B |
| Net income | $10.2B | $20.6B |
| Gross margin | 81.9% | 83.0% |
| Net margin | 17.4% | 31.7% |
| Return on equity | 22.9% | 101.2% |
| Diluted EPS | $6.54 | $22.95 |
| Dividend / share | $3.13 | $6.23 |
| Payout ratio | 48.6% | 26.1% |
| Free cash flow | $11.8B | · |
| Equity | $48.7B | $26.5B |
| Net debt / equity | 0.49× | 1.33× |
| Current ratio | 0.94× | 1.58× |
| Revenue CAGR 5y | 17.2% | 21.6% |
| Profit CAGR 5y | 26.2% | 27.2% |
AZN and LLY book revenue within 15% of each other, and LLY keeps more of each dollar of revenue as profit (31.7% against 17.4%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AZN | LLY |
|---|---|---|
| FY2025 | $58.7B | $65.2B |
| FY2024 | $54.1B | $45.0B |
| FY2023 | $45.8B | $34.1B |
| FY2022 | $44.4B | $28.5B |
| FY2021 | $37.4B | $28.3B |
| FY2020 | $26.6B | $24.5B |
| FY2019 | $24.4B | $22.3B |
| FY2018 | $22.1B | $21.5B |
| FY2017 | $22.5B | $20.0B |
| FY2016 | $23.0B | $21.2B |
Bottom line
| Fiscal year | AZN | LLY |
|---|---|---|
| FY2025 | $10.2B | $20.6B |
| FY2024 | $7.0B | $10.6B |
| FY2023 | $6.0B | $5.2B |
| FY2022 | $3.3B | $6.2B |
| FY2021 | $112.0M | $5.6B |
| FY2020 | $3.2B | $6.2B |
| FY2019 | $1.3B | $8.3B |
| FY2018 | $2.2B | $3.2B |
| FY2017 | $3.0B | $-204.1M |
| FY2016 | $3.5B | $2.7B |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$6,440,000,000 | LLY |
| FY2024 | +$9,030,000,000 | AZN |
| FY2023 | +$11,687,000,000 | AZN |
| FY2022 | +$15,809,600,000 | AZN |
| FY2021 | +$9,098,600,000 | AZN |
| FY2020 | +$2,077,200,000 | AZN |
| FY2019 | +$2,064,500,000 | AZN |
| FY2018 | +$596,700,000 | AZN |
| FY2017 | +$2,491,200,000 | AZN |
| FY2016 | +$1,779,900,000 | AZN |
| FY2015 | +$4,749,300,000 | AZN |
The higher-revenue side has changed between AZN and LLY over this period. The gap has widened since the earliest year compared.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −14.2 pp | LLY |
| FY2024 | −10.5 pp | LLY |
| FY2023 | −2.3 pp | LLY |
| FY2022 | −14.5 pp | LLY |
| FY2021 | −19.4 pp | LLY |
| FY2020 | −13.4 pp | LLY |
| FY2019 | −32.2 pp | LLY |
| FY2018 | −5.8 pp | LLY |
| FY2017 | +13.8 pp | AZN |
| FY2016 | +1.9 pp | AZN |
| FY2015 | −0.6 pp | LLY |
The higher net margin has changed hands between AZN and LLY over this period.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LLY's net margin has been more volatile than AZN's over the 11 comparable fiscal years — 9.9 percentage points of standard deviation against 4.6.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AZN and LLY over these 11 fiscal years — AZN led in 2 and LLY in 9.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LLY's return on equity has been more volatile than AZN's over the 11 comparable fiscal years — 46.9 percentage points of standard deviation against 6.4.
11 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AZN and LLY over these 11 fiscal years — AZN led in 2 and LLY in 9.
11 of 18 comparable fiscal years — a year missing data on either side is not counted.